Get opinion pieces, letters and editorials sent directly to your inbox weekly!
Teplizumab, developed by Provention Bio, typically delays the need for insulin shots, blood-sugar monitoring, and diet control by about two years or longer. Alexis Stanley shows her insulin kit in St. Paul, Minnesota.
In a first, the U.S. Food and Drug Administration has approved a therapy that slows the onset of Type 1 diabetes. Teplizumab, developed by Provention Bio, typically delays the need for insulin shots, blood-sugar monitoring, and diet control by about two years. For some, the effect lasted years longer.
The treatment could be a way to delay the life-changing regime of managing diabetes, which is often diagnosed in children or adolescence. Unfortunately, there are many hurdles to overcome before the drug can make a real difference. The most immediate and daunting problem: getting the treatment to the right people at the right time.
A drug that can slow the onset of the disease is a gift to people destined to develop Type 1 diabetes, which affects roughly 1-1.5 million Americans. “You don’t do anything if you have diabetes without thinking about the diabetes,” says Kevan Herold, a professor at Yale School of Medicine who was involved with the clinical studies of teplizumab. “You don’t eat, you don’t exercise, you don’t sleep, you don’t go to school — it’s there all the time.”
Type 1 diabetes occurs when the immune system wages war on beta cells, the clusters of insulin-making factories in the pancreas. Eventually, so many of those factories have been depleted that people become reliant on insulin injections to regulate their blood sugar. (By contrast, people with Type 2 diabetes can often still make insulin but can’t process it.)
Provention’s drug intervenes in that early battle. The antibody, administered as a daily infusion over the course of two weeks, dampens the activity of the immune cells that are causing the damage.
Maximizing that effect will be a huge challenge. For one, insurers will need to get on board. They may balk at a one-time regimen that costs nearly $200,000 yet still isn’t a cure.
The other issue is finding patients. To participate in the study that led to the drug’s approval, volunteers had to meet a number of criteria: a family member with Type 1 diabetes, at least two markers of the disease, called autoantibodies, and signs of blood sugar dysregulation.
Those criteria describe a small subset of a much larger population of people with Type 1 diabetes. The vast majority, some 85%–90%, don’t have a familial link to the disease. Nor is it a routine part of pediatric care to screen for it. And for good reason: the tests can be expensive and unpleasant (as anyone who has been pregnant may remember).
There are two ways to figure out who might benefit from the drug, according to JDRF, a diabetes-focused advocacy group that helped fund the development of tepliziumab through its venture philanthropy arm. The first would be to look for genetic markers linked to the disease in the heel-prick test every baby gets at the hospital. Not everyone who has those markers will go on to develop diabetes, but the screen could flag children who should be more closely monitored during their early life, says JDRF chief executive officer Aaron J. Kowalski.
The second approach is to look for the autoantibodies detectable in blood before symptoms show up. Researchers have found that a person with two or more of these markers along with abnormal blood sugar has a 75% chance of needing to rely on insulin within the next five years — and a nearly 100% chance of it in their lifetime.
But those tests need to become much more user-friendly and affordable, an effort JDRF is funding. It’s a scientific challenge more diagnostics companies should tackle.
If the right patients can be more readily identified — and that’s still a big if — the other question is whether the benefits of the drug can be strengthened. Teplizumab is currently approved as a one-time regimen. But doctors want to know if Type 1 diabetes could be further delayed if, for example, the treatment was administered repeatedly — and if so, how often? And could it help people newly diagnosed, who might still have some functioning beta cells to preserve?
Instead of a two-year delay, “wouldn’t it be nice if it was 8-10 years? Or 10-20 years? Or obliterated altogether?” says Bruce Perkins, director of the Sinai Centre for Diabetes, at Toronto’s Mount Sinai Hospital. “This is just the starting point, but it gives us so much hope.”
That hope took decades to materialize. The treatment traded hands among biotech and pharma companies as it trudged through clinical studies. It took several champions, and investment from JDRF’s venture philanthropy group, to finally heave the drug over the finish line.
It’s rare to land on treatments that can so clearly delay the course of a disease — not to mention ones that whisper of putting off the disease for long enough they start to look like prevention. Getting this therapy to the people who need it shouldn’t also be a years-long slog.
Get opinion pieces, letters and editorials sent directly to your inbox weekly!
Something is altering the normal seasonal currents of cold and flu viruses. They slowed to a trickle during the early part of the COVID-19 pandemic only to blast through human populations this year. Some public health experts have called it a “tripledemic,” but it might even be described as a quadrupledemic. In the Northern Hemisphere, flu began surging in October, months before its normal …
Sleep is finally having its moment. I’m a sleep researcher and clinician, and it’s exhilarating to see broader recognition that sleep is important, yet I am often dismayed about the framing of why sleep is valuable. Messages equating sleep with laziness have long been woven into our cultural consciousness, with aphorisms such as “I’ll sleep when I’m dead” and “the early bird gets the worm” …
Every year, global climate summits feature a parade of hypocrisy as the world’s elite arrive on private jets to lecture humanity on cutting ca…
Recently Jessica Tarlov, the co-host of the hit Fox News talk show “The Five,” saw some social media posts speculating that she would soon be fired.
🎧 The hosts discuss whether this movement, which has gotten much attention after the fall of FTX, is an effective way to tackle society’s biggest problems.
To no one’s surprise, Attorney General Merrick Garland has appointed a special prosecutor, Jack Smith, to investigate former President Donald Trump. You might think that you’ve seen this movie before. But there’s little reason to think this will be a repeat of the Robert Mueller investigation that declined to bring charges against Trump. Charges are more likely this time around — though that …
For the past two years, Democratic Speaker Nancy Pelosi has conducted a political science class in how to manage the House of Representatives with a bare four-seat majority. The result, backed by a Democratic White House and Senate, has been a spate of significant bipartisan legislation – a long-sought infrastructure bill and measures spurring domestic chips production, expanding veterans’ …
Wealth and income inequality have recently gone down in the U.S. and other parts of the West, and the decline has been going on for the better part of the last decade. Yet it is not clear, to me at least, whether this is something to celebrate. The recent decrease should come as no surprise. Markets are well below their late 2021 levels, and the wealthy hold a disproportionate share of the …
It’s an unfortunate thing that the fiery collapse of the crypto exchange FTX is giving many people their first look at one of the most promising charitable movements of the last decade. It’s called effective altruism, or EA, and in recent years, disgraced FTX founder Sam Bankman-Fried, known as SBF, has arguably been the most famous — or maybe just the richest — effective altruist in the …
The GOP finally managed to take control of the House of Representatives. So, what should pro-life lawmakers do to advance their cause in the next Congress? Some may be tempted to avoid this topic altogether, as too many Republicans did for the last several months. But silence isn’t an acceptable strategy. Instead, they should go on offense and advance policies that protect innocent unborn life …
Sign up for a digital subscription to The Press of Atlantic City now and take advantage of a great offer.
Teplizumab, developed by Provention Bio, typically delays the need for insulin shots, blood-sugar monitoring, and diet control by about two years or longer. Alexis Stanley shows her insulin kit in St. Paul, Minnesota.
Get up-to-the-minute news sent straight to your device.